Testing Two 'Sleep Peptides' in Rats: Neither DSIP nor AVT Actually Promoted Sleep

What the researchers found

DSIP administered systemically (40-160 nmol/kg) did not significantly reduce motor activity over 24 hours, and neither injection nor infusion of DSIP into brain ventricles (7-24 nmol) significantly increased sleep or EEG delta power. AVT injected into brain ventricles at extremely low doses (10⁻¹⁵ to 10⁻¹⁹ mol) similarly failed to enhance sleep.

However, both peptides showed biological activity: DSIP at 160 nmol/kg reduced dark-time motor activity 1-2 days after administration, and at 80 nmol/kg it paradoxically increased activity in the first 4 hours. Both DSIP and AVT reduced delta-band EEG power when administered into the third ventricle — the opposite of what a sleep-promoting substance would do. AVT's effects at femtomolar doses were notable, suggesting biological activity at concentrations far below typical peptide drug ranges.

Why it matters

DSIP was originally isolated and named for its apparent ability to induce slow-wave sleep, and it became widely referenced in the peptide supplement community. This early negative study is important because it challenged the foundational claim about DSIP's sleep-promoting properties using rigorous EEG and behavioral methods. It helped establish that DSIP's effects are more complex and less specific than its name implies.

How the study worked

Rats received DSIP via systemic injection (intraperitoneal) or direct brain ventricle infusion at multiple doses. AVT was administered into brain ventricles at extremely low concentrations. Motor activity was monitored over 24 hours, and sleep architecture was assessed using EEG recordings, with particular attention to delta-band power (the signature of deep slow-wave sleep).

What this study cannot tell us

This was a rat study, and sleep architecture differs significantly between rodents and humans. The sample size was not reported in the abstract. DSIP's effects on sleep may be species-specific or require specific conditions not replicated in this experimental setup. The study tested a limited range of doses and timing protocols — it's possible that different regimens might produce different results.

How to read the evidence

This is a controlled animal study with EEG measurements providing objective sleep data. While methodologically sound for its time, the small scope (rats only, limited dose range) and 1980 publication date mean the findings should be considered alongside the broader, mixed DSIP literature.

When this study was published

Published in 1980, this is one of the early studies that began to question DSIP's reputation as a sleep-inducing peptide. The fundamental finding — that DSIP is not a specific sleep promoter — has been largely consistent with subsequent research.

The bigger picture

This 1980 study is part of a broader story about how peptides discovered in the mid-20th century were often named for their initial observed effects before those effects were fully validated. DSIP remains commercially available as a supplement despite decades of inconsistent sleep data. The study also highlighted AVT's remarkable potency at femtomolar doses, contributing to ongoing research into ultra-low-dose neuropeptide signaling. The search for genuine sleep-promoting peptides has since shifted to other candidates like orexin antagonists.

Questions still open

• If DSIP doesn't directly promote sleep, what accounts for the subjective sleep improvements reported by some human users?
• How does AVT exert measurable electrophysiological effects at femtomolar concentrations — far below typical receptor binding thresholds?

Common questions

Read the original research

Effect of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity in the rat.

Waking and sleeping, 4(2), 139-53

Citation

Tobler, I; Borbély, A A. (1980). Effect of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity in the rat.. Waking and sleeping, 4(2), 139-53.